Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 66, n° 4
pages 673-679 (avril 2012)
Doi : 10.1016/j.jaad.2011.08.025

Leflunomide in dermatology

Alan S. Boyd, MD
Departments of Medicine (Dermatology) and Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee 

Reprint requests: Alan S. Boyd, MD, 719 Thompson Ln, Suite 26300, Nashville, TN 37204.

Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis. This drug inhibits dihydroorotate dehydrogenase, an enzyme critical in the production of intracellular pyrimidines, and down-regulates tumor necrosis factor-alfa activity. Leflunomide has demonstrated usefulness in treating cutaneous psoriasis along with other dermatologic and rheumatologic conditions.

The full text of this article is available in PDF format.

Key words : atopic dermatitis, dihydroorotate dehydrogenase, leflunomide, psoriasis, psoriatic arthritis, rheumatoid arthritis, tumor necrosis factor-alfa

 Funding sources: None.
 Conflicts of interest: None declared.

© 2011  American Academy of Dermatology, Inc.@@#104156@@